Equities
Health CareHealth Care Equipment & Services
  • Price (NOK)14.50
  • Today's Change-0.35 / -2.36%
  • Shares traded923.22k
  • 1 Year change-28.58%
  • Beta1.9298
Data delayed at least 15 minutes, as of Oct 21 2020 15:25 BST.
More ▼

Profile data is unavailable for this security.

About the company

Nordic Nanovector ASA is a Norway-based company active in the biotechnology industry. It is engaged in the development and commercialization of targeted therapeutics for hematological cancers. Its main product candidate is Betalutin, comprising a tumor-seeking anti-CD37 antibody conjugated to a low intensity radionuclide (Lutetium 177). It is designed improve treatment of Non-Hodgkin Lymphoma (NHL) and advanced through clinical development. Additionally, the Company is engaged in the development of its Antibody-Radionuclide-Conjugate (ARC) portfolio to treat various selected cancer indications. It has two subsidiaries, Nordic Nanovector GmbH and Nordic Nanovector Ltd.

  • Revenue in NOK (TTM)0.00
  • Net income in NOK-450.11m
  • Incorporated2009
  • Employees44.00
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Immunicum AB0.00-137.73m829.78m11.00--3.64-----1.37-1.370.002.330.00----0.00-42.36---46.28-------------164.740.00-------36.95------
Fluoguide AS0.00-23.33m838.33m----43.17-----1.93-1.930.001.250.00-------83.08---127.23-------------880.230.00-------18,054.97------
Dextech Medical AB0.00-8.19m839.23m1.00--60.41-----0.5202-0.52020.000.87740.00----0.00-43.14-33.23-45.53-34.61--6,195.06---8,425.14----0.00------7.68---39.91--
Hamlet Pharma AB0.00-24.87m899.26m2.00--80.88-----0.7094-0.70940.000.31160.00-------181.37-72.22-253.18-81.15-----------2,258.62---------37.01------
Scandion Oncology A/S0.00-19.95m915.99m----49.54-----0.9936-0.99360.000.81320.00-------124.52---147.73--------------0.00-------48.90------
Gentian Diagnostics AS60.05m-19.19m1.11bn46.00--5.46--18.46-1.25-1.253.9013.190.26521.737.501,305,435.00-8.47---8.92--49.47---31.96--14.08--0.0305--20.14---101.31------
SynAct Pharma AB0.00-24.73m1.21bn----252.36-----1.45-1.450.000.18550.00-------190.07---1,548.73-------------14.580.00-------2.19------
Nordic Nanovector ASA0.00-450.11m1.21bn44.00--6.11-----7.15-7.150.002.430.00----0.00-113.27-42.23-157.77-47.93-------139,959.00----0.021-------28.37---7.60--
Ascelia Pharma AB0.00-93.45m1.24bn----3.44-----3.72-3.720.0012.080.00-------29.52---31.39-------------30.570.0041--------------
Xbrane Biopharma AB0.00-205.41m1.33bn42.00--8.22-----11.98-11.980.009.920.003.67--0.00-43.36-35.81-77.92-57.59---36.61---633.441.49-186.740.0395---100.00---1,154.44--44.68--
Kancera AB2.93m-43.24m1.39bn15.00--17.03--476.53-0.1733-0.17330.01120.17710.043--0.4613137,900.00-63.46-75.82-77.23-97.4498.3091.14-1,477.45-4,212.02---57.550.00--798.3246.9121.42------
BioPorto A/S35.68m-100.55m1.40bn26.00--24.18--39.10-0.3254-0.32540.11470.14680.33532.263.44711,882.40-94.48-63.92-125.13-74.6864.1271.14-281.77-145.902.12-312.190.2709--2.337.31-83.04--6.51--
Isofol Medical AB (publ)0.00-216.60m1.43bn12.00--8.93-----4.53-4.530.001.810.00----0.00-90.90-55.58-114.65-62.95------------0.0153-------94.39------
Vicore Pharma Holding AB0.00-109.38m1.48bn13.00--4.27-----2.18-2.180.005.410.00----0.00-36.81-24.26-38.71-25.68-------5,367.50----0.0005---100.00---329.33---56.55--
SyntheticMR AB47.77m-3.37m1.48bn23.00--33.691,374.5031.06-0.7849-0.784911.1410.270.8289--4.761,875,458.00-5.8415.47-7.3018.68105.87108.67-7.0418.85---68.610.0383---5.1890.04-74.55--7.44--
BioInvent International AB80.45m-159.23m1.61bn72.00--4.87--19.96-0.3035-0.30350.15340.32560.2672--1.581,052,806.00-52.88-66.79-65.29-86.88-----197.94-194.924.22-292.050.0613--143.1814.84-12.56--56.11--
Data as of Oct 21 2020. Currency figures normalised to Nordic Nanovector ASA's reporting currency: Norwegian Krone NOK

Institutional shareholders

13.12%Per cent of shares held by top holders
HolderShares% Held
Folketrygdfondetas of 02 Jul 20203.66m5.05%
Nordea Investment Management AB (Norway)as of 31 Aug 20201.95m2.69%
KLP Kapitalforvaltning ASas of 30 Sep 20201.07m1.48%
Storebrand Asset Management ASas of 30 Sep 20201.03m1.43%
Equinor Asset Management ASAas of 02 Jul 2020480.87k0.66%
Dimensional Fund Advisors LPas of 31 Aug 2020421.96k0.58%
Max Mitteregger Kapitalf�rvaltning ABas of 31 Dec 2016300.00k0.41%
DNB Asset Management ASas of 31 Aug 2020299.34k0.41%
Handelsbanken Fonder ABas of 30 Sep 2020148.62k0.21%
ARIAD Asset Management GmbHas of 31 Aug 2020144.31k0.20%
More ▼
Data from 31 Dec 2016 - 02 Oct 2020Source: FactSet Research Systems Inc.
The Financial and Risk business of Thomson Reuters is now Refinitiv
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.